NYSE: MCKMckesson Corp Stock
$940.91-3.45 (-0.37%)
Updated Mar 13, 2026
MCK Price
$940.91
Fair Value Price
N/A
Market Cap
$115.25B
52 Week Low
$637.00
52 Week High
$999.00
P/E
27.01x
P/B
-88.79x
P/S
0.25x
PEG
2.04x
Dividend Yield
0.34%
Revenue
$397.96B
Earnings
$4.34B
Gross Margin
3.6%
Operating Margin
1.41%
Profit Margin
1.1%
Debt to Equity
-65.56
Operating Cash Flow
$10B
Beta
0.28
Next Earnings
May 13, 2026
Ex-Dividend
N/A
Next Dividend
Apr 1, 2026
MCK Overview
McKesson Corporation distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the U.S. and internationally. It also provides practice management, technology, clinical support, and business solutions to concology and other specialty practices, as well as consulting services to pharmacies. McKesson was founded in 1833 and is headquartered in Irving, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MCK's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Distribution
Industry Rating
A
MCK
Ranked#3 of 6
Ranked#3 of 6
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $75.57 | B | |
| $217.08 | B | |
| $349.95 | C |
Be the first to know about important MCK news, forecast changes, insider trades & much more!
MCK News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MCK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MCK ($940.91) is trading above its intrinsic value of $352.38, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MCK is good value based on its earnings relative to its share price (27.01x), compared to the US market average (31.87x)
P/E vs Market Valuation
MCK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MCK due diligence checks available for Premium users.
Valuation
MCK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.01x
Industry
31.63x
Market
31.87x
MCK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MCK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MCK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-88.79x
Industry
325.51x
MCK price to earnings growth (PEG)
For valuing profitable companies with growth potential
MCK is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MCK's financial health
Profit margin
Revenue
$106.2B
Net Income
$1.2B
Profit Margin
1.1%
MCK's Earnings (EBIT) of $5.61B... subscribe to Premium to read more.
Interest Coverage Financials
MCK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$84.2B
Liabilities
$85.1B
Debt to equity
-65.56
MCK's short-term liabilities ($68.13B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MCK's short-term assets ($59.70B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MCK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MCK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.2B
Investing
-$269.0M
Financing
-$2.0B
MCK's operating cash flow ($10.48B)... subscribe to Premium to read more.
Debt Coverage Financials
MCK vs Medical Distribution Stocks
Mckesson Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.